NCT02039245View on ClinicalTrials.gov

Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

February 28, 2014

Study Completion Date

March 31, 2014

Conditions

Healthy Volunteers

Interventions

DRUG

CANA/MET XR FDC

Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)

Trial Locations (1)

Unknown

Neptune City

All Listed Sponsors

lead

Janssen Research & Development, LLC

INDUSTRY

NCT02039245 - Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination | Biotech Hunter | Biotech Hunter